Abstract
Integrins are a family of heterodimeric receptors, which modulate many cellular processes including: growth, death (apoptosis), adhesion, migration, and invasion by activating several signaling pathways. Integrin-binding RGD (arginine- glycine-aspartic acid) is found in several important extracellular matrix proteins which serve as adhesive integrin ligands. The RGD motif has also been found in many toxins from snake venom and other sources that specifically inhibit integrin binding function and serve as potent integrin antagonists, particularly of platelet aggregation and integrinmediated cell adhesion. Many of these proteins have potential as therapeutic agents which can target integrins directly. Structural and functional studies of several RGD-containing toxins suggest that the inhibitory potency of these proteins lies in subtle positional requirements of the tripeptide RGD at the tip of a flexible loop, a structural feature for binding to integrins. In addition, amino acid residues in this loop in close vicinity to the RGD-motif determine the integrin-binding specificity and selectivity. This review will present a review of integrin structure and function, and of disintegrin structural features responsible for their activity as antagonists of integrin function. The use of integrins in drug targeting and integrins as targets for drug delivery by using the RGD as a template structure will also be discussed
Keywords: ADAM proteins, antagonist, cell adhesion, disintegrin, integrin, platelet aggregation, RGD-motif, venom toxins
Current Pharmaceutical Design
Title: Integrins in Drug Targeting-RGD Templates in Toxins
Volume: 12 Issue: 22
Author(s): X. Lu, D. Lu, M. F. Scully and V. V. Kakkar
Affiliation:
Keywords: ADAM proteins, antagonist, cell adhesion, disintegrin, integrin, platelet aggregation, RGD-motif, venom toxins
Abstract: Integrins are a family of heterodimeric receptors, which modulate many cellular processes including: growth, death (apoptosis), adhesion, migration, and invasion by activating several signaling pathways. Integrin-binding RGD (arginine- glycine-aspartic acid) is found in several important extracellular matrix proteins which serve as adhesive integrin ligands. The RGD motif has also been found in many toxins from snake venom and other sources that specifically inhibit integrin binding function and serve as potent integrin antagonists, particularly of platelet aggregation and integrinmediated cell adhesion. Many of these proteins have potential as therapeutic agents which can target integrins directly. Structural and functional studies of several RGD-containing toxins suggest that the inhibitory potency of these proteins lies in subtle positional requirements of the tripeptide RGD at the tip of a flexible loop, a structural feature for binding to integrins. In addition, amino acid residues in this loop in close vicinity to the RGD-motif determine the integrin-binding specificity and selectivity. This review will present a review of integrin structure and function, and of disintegrin structural features responsible for their activity as antagonists of integrin function. The use of integrins in drug targeting and integrins as targets for drug delivery by using the RGD as a template structure will also be discussed
Export Options
About this article
Cite this article as:
Lu X., Lu D., Scully F. M. and Kakkar V. V., Integrins in Drug Targeting-RGD Templates in Toxins, Current Pharmaceutical Design 2006; 12 (22) . https://dx.doi.org/10.2174/138161206777947713
DOI https://dx.doi.org/10.2174/138161206777947713 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry Regulation of Tumor Immune Microenvironment by Sphingolipids and Lysophosphatidic Acid
Current Drug Targets Telocytes as a Source of Progenitor Cells in Regeneration and Repair Through Granulation Tissue
Current Stem Cell Research & Therapy The Current Status of Cryotherapy and High-Intensity Focused UltraSound in the Treatment of Low-Grade Prostate Cancer
Reviews on Recent Clinical Trials Nutritional Antioxidants and Adaptive Cell Responses: An Update
Current Molecular Medicine Application of Bacterial Nanocellulose in Cancer Drug Delivery: A Review
Current Pharmaceutical Design Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line
Current Gene Therapy Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry The Post Hoc Use of Randomised Controlled Trials to Explore Drug Associated Cancer Outcomes: Methodological Challenges
Current Drug Safety Deregulation of HOX B13 Expression in Urinary Bladder Cancer Progression
Current Medicinal Chemistry Application of Efficient Nanoparticles for Early Diagnosis and Treatment of Cancer
Current Drug Metabolism Labeling Polyamidoamine (PAMAM) Dendrimers with Technetium-99m via Hydrazinonicotinamide (HYNIC)
Current Radiopharmaceuticals Synthesis and Evaluation of 99mTc Chelate-conjugated Bevacizumab
Current Radiopharmaceuticals The State-of-Art in Angiogenic Properties of Latex from Different Plant Species
Current Angiogenesis (Discontinued) Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic Ion Fluxes and Cancer (Guest Editors: Luca Munaron and Annarosa Arcangeli)]
Recent Patents on Anti-Cancer Drug Discovery In Vitro Regulatory Effect of Epididymal Serpin CRES on Protease Activity of Proprotein Convertase PC4/PCSK4
Current Molecular Medicine General Aspects of Metal Toxicity
Current Medicinal Chemistry Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology